Patient-derived sarcoma xenografts for individual-patient selection of chemotherapy - Ready for prime time?

Cancer

Volumn 120, Issue 13, 2014, Pages 1917-1919

  Wagner, Andrew J ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IRINOTECAN; REGORAFENIB; TEMOZOLOMIDE;

CANCER CHEMOTHERAPY; CHEMOSENSITIVITY; CLINICAL PRACTICE; EDITORIAL; EXTRACELLULAR MATRIX; HUMAN; KIDNEY CARCINOMA; LIPOSARCOMA; MEDICAID; MEDICARE; MELANOMA; MYXOMA; OVERALL SURVIVAL; PATIENT SELECTION; PRACTICE GUIDELINE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SARCOMA; TUMOR XENOGRAFT; VASCULARIZATION;

ANIMALS; FEMALE; HETEROGRAFTS; HUMANS; INDIVIDUALIZED MEDICINE; MALE; SARCOMA; TRANSPLANTATION, HETEROLOGOUS;

EID: 84902533728     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.28694     Document Type: Editorial

References (15)

1. Fruehauf JP, Alberts DS,. In vitro drug resistance versus chemosensitivity: 2 sides of different coins. J Clin Oncol 23: 3641-3643, 2005; author reply 3646-3648.
2. Castro M,. Resisting a fundamentalist policy. J Clin Oncol. 2005; 23: 3645-3646.
3. Cree IA, Kurbacher CM, Lamont A, Hindley AC, Love S,; TCA Ovarian Cancer Trial Group. A prospective randomized controlled trial of tumour chemosensitivity assay directed chemotherapy versus physician's choice in patients with recurrent platinum-resistant ovarian cancer. Anticancer Drugs. 2007; 18: 1093-1101.
4. Samson DJ, Seidenfeld J, Ziegler K, Aronson N,. Chemotherapy sensitivity and resistance assays: a systematic review. J Clin Oncol. 2004; 22: 3618-3630.
5. Centers for Medicare and Medicaid Services (CMS). MEDCAC Meeting 11/15/1999-Human Tumor Assay Systems (Laboratory and Diagnostic Services Panel). Available at: http://www.cms.gov/medicare-coverage-database/details/medcac- meeting-details.aspx?MEDCACId=14&NCAId=36&NcaName= Human+Tumor+Assay+Systems&NCDId=253&ncdver=1&SearchType= Advanced&CoverageSelection=National&NCSelection= NCA|CAL|NCD|MEDCAC|TA|MCD&KeyWord=chemosensitivity&KeyWordLookUp= Doc&KeyWordSearchType=Exact&kq=true&IsPopup=y&bc= AAAAAAAACAAAAA%3d%3d&. Accessed February 3, 2014.
6. Schrag D, Garewal HS, Burstein HJ, Samson DJ, Von Hoff DD, Somerfield MR,. American Society of Clinical Oncology technology assessment: chemotherapy sensitivity and resistance assays. J Clin Oncol. 2004; 22: 3631-3638.
7. Burstein HJ, Mangu PB, Somerfield MR, et al. American Society of Clinical Oncology clinical practice guideline update on the use of chemotherapy sensitivity and resistance assays. J Clin Oncol. 2011; 29: 3328-3330.
8. Aetna. Aetna clinical Policy Bulletin: Tumor Chemosensitivity Assays. Available at: http://www.aetna.com/cpb/medical/data/200-299/0245.html. Accessed February 3, 2014.
9. BlueCross BlueShield of North Carolina. BlueCross BlueShield of North Carolina Corporate Medical Policy: In Vitro Chemoresistance and Chemosensitivity Assays. Available at: http://www.bcbsnc.com/assets/services/public/pdfs/ medicalpolicy/in-vitro-chemoresistance-and-chemosensitivity-assays.pdf. Accessed February 3, 2014.
10. Anthem. Anthem Medical Policy: In Vitro Chemosensitivity Assays and In Vitro Chemoresistance Assays. Available at: http://www.anthem.com/ medicalpolicies/policies/mp-pw-a049881.htm. Accessed February 3, 2014.
11. United Healthcare. United Healthcare Medical Policy: Chemosensitivity and Chemoresistance Assays in Cancer. Available at: https://www. unitedhealthcareonline.com/ccmcontent/ProviderII/UHC/en-US/Assets/ ProviderStaticFiles/ProviderStaticFilesPdf/Tools%20and%20Resources/ Policies%20and%20Protocols/Medical%20Policies/Medical%20Policies/ Chemosensitivity-and-Chemoresistance-Assays.pdf. Accessed February 3, 2014.
12. Harvard Pilgrim Health Care. Harvard Pilgrim Health Care Medical Policy: In Vitro Chemosensitivity and Chemoresistance Assays. Available at: https://www.harvardpilgrim.org/pls/portal/docs/PAGE/PROVIDERS/MEDMGMT/ STATEMENTS/CHEMOSENS-ASSAYS-0912.pdf. Accessed February 3, 2014.
13. CareAllies. CareAllies Medical Necessity Guidelines: Tumor In Vitro Chemosensitivity and Chemoresistance Assays. Available at: http://www.cigna.com/ sites/careallies/pdf/CA0203-tumor-in-vitro-chemosensitivity-assays.pdf. Accessed February 3, 2014.
14. Centers for Medicare and Medicaid Services (CMS). CMS Local Coverage Determination: In Vitro Chemosensitivity and Chemoresistance Assays (L31708). Available at: http://www.cms.gov/medicare-coverage-database/details/lcd-details. aspx?LCDId=31708&ContrId=234&ver=20&ContrVer=1&date=&docID= L31708+&SearchType=Advanced&bc=KAAAAAgAAAAAAA%3d%3d&. Accessed February 3, 2014.
15. Stebbing J, Pas K, Schwartz GK, et al. Patient-derived xenografts for individualized cancer care in advanced sarcoma. Cancer. 2014; 120: 2006-2014.